Correlation Between Monte Rosa and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Monte Rosa and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monte Rosa and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monte Rosa Therapeutics and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Monte Rosa and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monte Rosa with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monte Rosa and Acrivon Therapeutics,.

Diversification Opportunities for Monte Rosa and Acrivon Therapeutics,

0.14

Correlation Coefficient

Monte Rosa  Acrivon Therapeutics,

Average diversification

The 3 months correlation between Monte and Acrivon is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Monte Rosa Therapeutics and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Monte Rosa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monte Rosa Therapeutics are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Monte Rosa i.e., Monte Rosa and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Monte Rosa and Acrivon Therapeutics,

Given the investment horizon of 90 days Monte Rosa Therapeutics is expected to under-perform the Acrivon Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Monte Rosa Therapeutics is 1.37 times less risky than Acrivon Therapeutics,. The stock trades about -0.52 of its potential returns per unit of risk. The Acrivon Therapeutics, Common is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  665.00  in Acrivon Therapeutics, Common on October 10, 2024 and sell it today you would lose (55.00) from holding Acrivon Therapeutics, Common or give up 8.27% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Monte Rosa Therapeutics  vs.  Acrivon Therapeutics, Common

Monte Rosa Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Acrivon Therapeutics, is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Monte Rosa and Acrivon Therapeutics,

The main advantage of trading using opposite Monte Rosa and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monte Rosa position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Monte Rosa Therapeutics and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.